Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

HCRN Tratamento endoscópico versus shunt para hidrocefalia em bebês (ESTHI)

22 de setembro de 2026 atualizado por: John Kestle, University of Utah

Tratamento endoscópico versus shunt de hidrocefalia em bebês

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby.

Visão geral do estudo

Descrição detalhada

The ESTHI Trial is a multi-center randomized controlled trial (RCT) comparing endoscopic third ventriculostomy with choroid plexus cauterization (ETV+CPC) and shunt in infants with hydrocephalus. The study will leverage the infrastructure of the Hydrocephalus Clinical Research Network (HCRN), a committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome is the primary concern of families and will, therefore, be the primary outcome. Assessment of dMRI, a validated, non-invasive method of measuring white matter microstructural integrity and structural connectivity in the developing brain, will provide further insight into the developmental consequences of these two treatments. The results of the RCT will help families determine the optimal treatment of hydrocephalus for their child.

Tipo de estudo

Intervencional

Inscrição (Real)

165

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alberta
      • Calgary, Alberta, Canadá, T3B 6A8
        • Alberta Children's Hospital
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • Toronto, Ontario, Canadá, M5G 1X8
        • The Hospital for Sick Children
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Children's of Alabama
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, Estados Unidos, 90027
        • Children's Hospital of Los Angeles
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Yale University
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32207
        • Wolfson Children's Hospital
      • Orlando, Florida, Estados Unidos, 32806
        • Arnold Palmer Hospital for Children
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Trustees of Indiana University
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins Children's Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • St. Louis Children's Hospital
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • Children's Hospital of Pittsburgh of UPMC
      • University Park, Pennsylvania, Estados Unidos, 16802
        • The Pennsylvania State University
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Texas Children's Hospital
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84118
        • Primary Children's Hospital
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23284
        • Virginia Commonwealth University
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Seattle Children's Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

1 dia a 1 ano (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Corrected age <104 weeks and 0 days,

    AND

  2. Child is ≥ 37 weeks post menstrual age,

    AND

  3. Child must have symptomatic hydrocephalus, defined as:

    Ventriculomegaly on MRI (frontal-occipital horn ratio (FOR) >0.45, which approximates "moderate ventriculomegaly"), and at least one of the following:

    • Head circumference >98th percentile for corrected age with either bulging fontanelle or splayed sutures
    • Upgaze paresis/palsy (sundowning)
    • CSF leak
    • Papilledema
    • Tense pseudomeningocele or tense fluid along a track
    • Vomiting or irritability, with no other attributable cause
    • Bradycardias or apneas, with no other attributable cause
    • Intracranial pressure (ICP) monitoring showing persistent elevation of pressure with or without plateau waves

    AND

  4. No prior history of shunt insertion or endoscopic third ventriculostomy (ETV) procedure (previous temporization devices and/or external ventricular drains permissible)

Exclusion Criteria:

  1. Hydrocephalus due to intraventricular hemorrhage in a child born before 37 weeks gestational age; OR

  2. Anatomy not suitable for ETV+CPC or anteriorly placed ventriculoperitoneal shunt defined as:

    • Moderate to severe prepontine adhesions on steady state free precession (SSFP) or T2 weighted fast (turbo) spin echo (FSE/TSE) MRI, which includes the following sequences: FIESTA, FIESTA-C, TrueFISP, CISS, Balanced FFE (bFFE), CUBE, SPACE, VISTA, IsoFSE, and 3D MVOX
    • Closure of one or both foramina of Monro
    • Thick floor of third ventricle (≥ 3mm)
    • Narrow third ventricle (<5mm)
    • Presence of scalp, bone, or ventricular lesions that make placement of an anterior shunt impracticable; OR
  3. Underlying condition with a high chance of mortality within 12 months; OR

  4. Hydrocephalus with loculated CSF compartments; OR

  5. Peritoneal cavity not suitable for distal shunt placement; OR

  6. Active CSF infection; OR

  7. Hydranencephaly; OR

  8. Child requires an intraventricular procedure (e.g. endoscopic biopsy) in addition to the initial first-time permanent procedure for the treatment of hydrocephalus.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: ETV+CPC

Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus

Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.

Comparador Ativo: Ventriculoperitoneal Shunt

Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus

The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Bayley Scale of Infant Development-IV (Bayley-IV) Cognitive Scale score
Prazo: 12 months post randomized surgical intervention

The primary objective is to determine, in infants <104 weeks corrected age, with hydrocephalus requiring treatment at tertiary care pediatric neurosurgery centers in North America, if treatment with ETV+CPC compared to shunt results in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley-IV Cognitive Scale score with a non-inferiority margin of 1.5. Scaled scores range from 1-19. Higher scores indicate better outcomes. Scores will also be obtained at 3 and 5 years of age.

12 months post randomized surgical intervention

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Bayley Scale of Infant Development-IV (Bayley-IV) Language Scaled Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Language Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Bayley Scale of Infant Development-IV (Bayley-IV) Motor Scaled Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Motor Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Vineland-3 Communication Domain Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Communication Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Daily Living Skills Domain Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Daily Living Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Socialization Domain Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Socialization Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Motor Skills Domain Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Motor Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Adaptive Behavior Composite Score
Prazo: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Adaptive Behavior Composite (ABC) scores. ABC scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
The occurrence of treatment failure.
Prazo: Through study completion, a maximum of 7 years.

Treatment failure is defined as obstruction, loculated compartments, overdrainage, CSF infection, or significant intraoperative complication. The rate of occurrence of each type, for the initial procedure, will be calculated. Failure can be captured at anytime during the course of the 7 year study. Occurrence between treatment arms will be compared.

Through study completion, a maximum of 7 years.
Time to failure.
Prazo: Through study completion, a maximum of 7 years

Time to failure is the number of days in which the intervention is functionally successful. It is calculated from date of surgery to date of failure, as described in Outcome 9. Time to failure between treatment arms will be compared.

Through study completion, a maximum of 7 years
Total number of hospital admission days within 12 months after surgery
Prazo: 12 months post randomized surgical intervention

Number of days subject is admitted to the hospital during the first 12 months following the initial surgical intervention. All hospital admissions included, regardless of reason for admission. Number of hospital admission days between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of repeat surgeries within 12 months after surgery
Prazo: 12 months post randomized surgical intervention

Number of shunt and ETV+CPC procedures during the first 12 months following the initial surgical intervention. Number of repeat surgeries between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of brain imaging (CT, MRI, ultrasound) scans within 12 months after surgery
Prazo: 12 months post randomized surgical intervention

Number of CT, MRI, and ultrasound brain scans during the first 12 months following the initial surgical intervention. Total imaging between treatment arms will be compared.

12 months post randomized surgical intervention
All major peri-operative and post-operative complications
Prazo: Through study completion, a maximum of 7 years

Number of peri-operative and post-operative complications to include those related to CSF circulation, infection, hemorrhage, seizures, and new neurological deficits. Number of complications between treatment arms will be compared.

Through study completion, a maximum of 7 years
Brain and ventricle volume on MRI performed at 12 months after surgery
Prazo: 12 months post randomized surgical intervention

Brain and CSF volumes will be converted to Z-scores based on previously described age- and sex-adjusted distributions and used for comparison of brain volume and growth between ETV+CPC and shunt treatment groups.

12 months post randomized surgical intervention
dMRI corpus collosum (CC) and corticospinal tract (CST) fractional anisotropy (FA) at 12 months after surgery.
Prazo: 12 months post randomized surgical intervention

Develop dMRI maps, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Tract-based spatial statistics (TBSS) will be used for voxel-wise analyses of white matter tracts. Maps will be used to compare cerebral structural connectivity between the two treatment arms.

12 months post randomized surgical intervention
Cerebral spinal fluid myelin basic protein (MBP) levels measured at the time of ETV+CPC or shunt
Prazo: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid myelin basic protein (MBP) levels to post-operative Bayley-IV Cognitive Scale score.

12 months post randomized surgical intervention
Cerebral spinal fluid amyloid precursor protein (APP) levels measured at the time of ETV+CPC or shunt
Prazo: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid amyloid precursor protein (APP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid NCAM-1 levels measured at the time of ETV+CPC or shunt
Prazo: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid NCAM-1 levels to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid glial fibrillary acid protein (GFAP) levels measured at the time of ETV+CPC or shunt
Prazo: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid glial fibrillary acid protein (GFAP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Wechsler Preschool & Primary Scale of Intelligence (WPPSI) Scores
Prazo: At 5 years of age

To determine, in infants who reach 5 years of age before the end of the study, if ETV+CPC compared to shunt results in non-inferior WPPSI scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

At 5 years of age
Health related quality of life (HRQoL) measurements
Prazo: 12 months post randomized surgical intervention, and at 3 and 5 years of age

To compare health-related quality of life (HRQoL), as measured by vi-sual analogue scales (VAS), Health Utilities Preschool (HuPS), and the Hydrocephalus Outcome Questionnaire (HOQ), between treatment arms.

12 months post randomized surgical intervention, and at 3 and 5 years of age

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de julho de 2020

Conclusão Primária (Estimado)

30 de maio de 2027

Conclusão do estudo (Estimado)

31 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

27 de outubro de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de novembro de 2019

Primeira postagem (Real)

26 de novembro de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

After subject enrollment and 5 year follow up have been completed, we will prepare a final study database for analysis. A releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. We will also prepare a data dictionary that provides a concise definition of every data element included in the database. If specific data elements have idiosyncrasies that might affect interpretation or analysis, this will be discussed in the dictionary document.

In accordance with policies determined by the investigators and funding sponsors, the releasable database will be provided to users in electronic form.

Prazo de Compartilhamento de IPD

Within one year of primary publication or within 18 months of the last study visit of the last subject, whichever occurs first.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever